We are pleased to announce that 42 investigators, from across BMC and the BU Medical & Charles River campuses, applied to the Integrated Pilot Award Program, sponsored by the BU Clinical and Translational Science Institute. From our pool of applications, 14 outstanding pilot projects were selected for funding, totaling an allocation of $645,000. We congratulate all of the recipients and look forward to your contributions to translational research.

Naltrexone for the Treatment of Cannabis Use Disorder in Pregnancy

Co-funded by BMC and BU CTSI


Kelley Saia, MD - Lead PI

Cecily Barber, MD, MPH

The primary objective of this study is to gain pilot data on the relative safety and efficacy of the use of Naltrexone (extended release; trade name: Vivitrol) (NTX) in pregnant persons with cannabis use disorder. The outcome measure of this study will be quantity of cannabis use, defined by survey and laboratory data assessing cannabis consumption. All key outcome measures are as follows: 1) participant outcomes [cannabis consumption, retention in care, preterm birth, and side effects / adverse events); 2) fetal outcomes (intrauterine growth, fetal anomalies).

Assessing and Addressing Implicit Bias within Healthcare-acquired Infections (AAIm HI)

Co-funded by BMC and DOM


Shana Burrowes, PhD, MPH - Lead PI

Cassandra Pierre, MD, MPH, MSC

Angelique C. Harris, PhD, MA

Implicit bias training is becoming more prevalent across healthcare but has not been used to specifically improve a targeted healthcare outcome. This proposal aims to reduce implicit bias in healthcare and innovate the use of implicit bias training to improve specific patient outcomes (i.e., HAIs) impacted by racial bias.